Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.
Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.
Crit Care. 2021 Oct 21;25(1):368. doi: 10.1186/s13054-021-03776-2.
Fever and hypothermia have been observed in septic patients. Their influence on prognosis is subject to ongoing debates.
We did a secondary analysis of a large clinical dataset from a quality improvement trial. A binary logistic regression model was calculated to assess the association of the thermal response with outcome and a multinomial regression model to assess factors associated with fever or hypothermia.
With 6542 analyzable cases we observed a bimodal temperature response characterized by fever or hypothermia, normothermia was rare. Hypothermia and high fever were both associated with higher lactate values. Hypothermia was associated with higher mortality, but this association was reduced after adjustment for other risk factors. Age, community-acquired sepsis, lower BMI and lower outside temperatures were associated with hypothermia while bacteremia and higher procalcitonin values were associated with high fever.
Septic patients show either a hypothermic or a fever response. Whether hypothermia is a maladaptive response, as indicated by the higher mortality in hypothermic patients, or an adaptive response in patients with limited metabolic reserves under colder environmental conditions, remains an open question. Trial registration The original trial whose dataset was analyzed was registered at ClinicalTrials.gov (NCT01187134) on August 23, 2010, the first patient was included on July 1, 2011.
发热和低体温在脓毒症患者中均有观察到。其对预后的影响仍存在争议。
我们对一项质量改进试验的大型临床数据集进行了二次分析。采用二项逻辑回归模型评估热反应与结局的相关性,采用多项回归模型评估与发热或低体温相关的因素。
在可分析的 6542 例病例中,我们观察到发热或低体温的双峰温度反应,体温正常较为罕见。低体温和高热均与较高的乳酸值相关。低体温与死亡率较高相关,但在调整其他危险因素后,这种相关性降低。年龄、社区获得性脓毒症、较低的 BMI 和较低的室外温度与低体温相关,而菌血症和较高的降钙素原值与高热相关。
脓毒症患者表现出低体温或发热反应。低体温是否是一种适应不良的反应,如低体温患者的死亡率较高所表明的那样,或者是在较冷的环境条件下代谢储备有限的患者的一种适应反应,仍是一个悬而未决的问题。
对其数据集进行分析的原始试验于 2010 年 8 月 23 日在 ClinicalTrials.gov(NCT01187134)注册,第一位患者于 2011 年 7 月 1 日纳入。